Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Rt.

Egis Gyogyszergyar

Arizona State University

Other

Arizona Board of Regents, a Body Corporate

Egis Gyogyszergyar Zrt.

Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag

Egis Gyogyszergyar Nyilvanosan Muekoedoe

Egis Gyogyszergynar Nyilvanosan Muekoedoe Reszvenytarsasag

Les Laboratoires Servier

Egis Gyogyszergyar Nyrt

Jozsef Barkoczy

Gyula Simig

Balazs Volk

Gabor Gigler

Kalman Nagy

Istvan Gacsalyi

Ferenc Lorant Bartha

Laszlo Pongo

George R Pettit

Adrienn Keszthelyi

Gyorgy Ruzsics

Lujza E Petocz

Marton Fekete

Istvan Gyertyan

Frigyes Gorgenyi

Jozsef Reiter

Zoltán Greff

Gyula Lukacs

Gyorgy Krasznai

Maria Tothne Lauritz

Eva Sipos

Gyoergy Ruzsics

Tibor Szabo

Eniko Szirt Nee Kiszelly

Gabor Nemeth

Istvan Ling

Krisztina Móricz

Janos Imre

Gyorgyi Kovanyine Lax

Andras Dancso

Peter Kotay Nagy

Zsuzsa Szent Kirallyi

Zoltan Ratkai

Jozsef Debreczeni

Gyoergyi Kovanyine Lax

Andras Boza

Geza Szabo

Imre Kiraly

Szabolcs Kertesz

Laszlo Balazs

Gabor Blasko

Klara Reiter Nee Esses

Michael Spedding

Márta Porcs-Makkay

Andras Egyed

Gábor Szénási

László Szlávik

Maria Szecsey Nee Hegedus

Darko Kantoci

Karoly Tihanyi

Zsuzsanna Szent-Királlyi

Enikó Molnár

Mátyás Milen

András Mravik

Balazs Havasi

Laszlo Harsing

Ferenc Antoni

Gyoergy Clementis

Éva Pécsi

Judit Broda

Laszlo Gabor Harsing

Angéla Pandur

Miklós Végh

Peter Seres

Imre Doman

Janos Petho

Peter Slegel

Imre Kapui

Hajnalka Kompagne

Lászlo Gabor Harsing

Agnes Kenez

Adrienn Palvolgyi

Gyula Szücs

Györgyi Vereczkeyne Donath

Ferenc Bertha

Bernadett Martonné Marko

Gyorgy Morovjan

György Levay

Lax Gyorgyi Kovanyine

Annamaria Simo

Gabor Bagyinszki

Ferenc Barta

Gyorgyi Vereczkeyne Donath

Gyoergy Morovjan

Gyoergy Krasznai

Balazs Mihalik

Valeria Hoffmanne Fekete

Imre Koehegyi

Laszlo Jozsef Hegedus

Maria Julia Taborine Toth

Adrienn Karasz

Agnes Angyalne Pataki

Marta Agoston

Gyoergy Levay

Gabor Laszlo Kapus

Maria Kovacs

Gabor Szenas

Gyorgy Levay

Compounds of formula (I) having a selective dual action on the central GABAergic system, and a process for their preparation and to pharmaceutical compositions containing them.

Dihydro-oxazinobenzodiazepine compounds, a process for their preparation and pharmaceutical compositions containing them

The invention relates to a process for the preparation of 5-chloro-N-({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-1,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The invention also relates to intermediates formed in the above process.

Process for the preparation of a rivaroxaban and intermediates formed in said process

The present invention relates to a process for the preparation of dabigatran etexilate of the formula 

Pharmaceutical intermediates and process for the preparation thereof

The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof.

Method for the preparation of high-purity pharmaceutical intermediates

The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates.

Method for preparing rosuvastatin salts

The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis.

Crystalline form I rosuvastatin zinc salt

The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.

Inorganic salt complexes of vildagliptin

The present invention relates to a new process for the preparation of rosuvastatin [7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulphonyl-methyl-amino)-pyrimidin-5-yl]-(3R,51S)-dihydroxy-hept-6-enoic acid] of the formula (I) salts formed with bivalent cations, preferably with calcium or zinc ions, characterized in that rosuvastatin tert.-butylammonium salt is reacted with the appropriate bivalent cation, preferably with calcium or zinc ions in a mixture of a water immiscible or slightly miscible organic solvent and water and the formed salt is isolated. 

Process for the preparation of rosuvastatin salts

The invention relates the use of 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxazole-3-yl)piperidin-1-yl]ethyl-amino}-2-methyl-3-(2H)pyridazinone of the Formula (I) or pharmaceutically acceptable salts thereof for the preparation of medicaments suitable for the improvement of cognitive function or obtaining neuroprotective effect. The medicaments containing 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxazol-3-yl)piperidin-1-yl]ethyl-amino}-2-methyl-3-(2H)pyridazinone of the Formula (I) or therapeutically acceptable salt thereof can be used for the treatment or prevention of neuronal death, mental decline, sclerosis multiplex, Creuzfeld-Jacobs disease, Huntington-syndrome, amyotrophic lateral sclerosis, Parkinson-disease, memory disturbance, loss of memory, amnesia, stroke or for the improvement of memory function or learning ability.

Medicament for the enhancement of cognitive function and neuroprotection

The invention relates to new 8-chloro-2,3-benzodiazepine derivatives of the general formula (I), wherein R stands for a lower alkyl group or a group of the general formula &#x2014;NH&#x2014;R', wherein R&#x2032; stands for a lower alkyl or a lower cycloalkyl group), and pharmaceutically acceptable acid addition salts thereof. The invention also encompasses a process for the preparation of said compounds, pharmaceutical compositions containing them and new intermediates useful for the preparation of the new 8-chloro-2,3-benzodiazepine derivatives. The compounds according to the invention possess AMPA/kainate receptor inhibiting activity. 

8-chloro-2,3-benzodiazepine derivatives

The invention relates to new crystalline forms I and II of (4R-cis)-6-[2-[3-phenyl-4-(phenyl-carbamoyl)-2-(4-fluoro-phenyl)-5-(1- methyl-ethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]dioxane-4-yl-acetic acid-tertiary butyl ester of the Formula (I) and a process for the preparation thereof. The new polymorphs of the present invention are useful pharmaceutical intermediates which can be used in the preparation of the hydroxymethyl-glutaryl coenzyme (HMG-COA) reducing enzyme inhibitor having the INN (International Non-proprietory Name) atorvastatin 

Polymorphs of a 1-pyrrole derivative, intermediate for the preparation of atorvastatin

The invention relates to new 2,3-benzodiazepine derivatives of general Formula (I), (wherein Rstands for methyl, formyl, carboxy, cyano, &#x2014;CH&#x2550;NOH, &#x2014;CH&#x2550;NNHCONHor &#x2014;NRR, wherein Rand Rindependently from each other represent hydrogen or lower alkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); Ris nitro or amino; Rstands for hydrogen, lower alkanoyl or CO&#x2014;NRR, wherein Rand Rindependently from each other stand for hydrogen, lower alkoxy, lower alkyl or lower cycloalkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); Ris hydrogen or lower alkyl; the dotted lines have the following meaning: if Rand Rare not present, the bond between positions Cand Cis a single bond and the bond between positions Cand Nis a double bond; if Rand Rare present, the bonds between positions Cand Cand between position Cand Nare single bonds; and if Ris present and Ris missing, the bond between positions Cand Cis a double bond and the bond between positions Cand Nis a single bond) and salts thereof. The invention compounds have neuroprotective effect.

2,3-benzodiazepine derivatives

The invention relates to a process for the preparation of amorphous atorvastatin calcium by recrystallization of crude atorvastatin from an organic solvent which comprises dissolving crude amorphous atorvastatin calcium in a lower alkanol containing 2-4 carbon atoms or a mixture of such alkanols under heating and isolating the amorphous atorvastatin calcium precipitated after cooling. The atorvastatin calcium obtained is a known valuable agent useful in treating hyperlipidemia and hypercholestrolemia.

Process for the preparation of amorphous atorvastatin calcium

Dolastatin 10, a linear pentapeptide, has shown potent antineoplastic activity profiles against various experimental cancer systems. The synthesis of structural modifications of dolastatin 10 having significant antineoplastic activity against human cancer cell lines has been accomplished; namely antineoplastic tetrapeptide w-amino alkyl amides related to dolastatin 10, which have been found to demonstrate effective antineoplastic activity against various human cancer cell lines. Members of this have demonstrated significant antineoplastic activity against human cancer cell lines. The human cancer cell lines against which the substances of the present invention have yielded the significant antineoplastic activity are: Ovarian OVCAR-3; Central Nervous System (&ldquo;CNS&rdquo;) SF295; Renal A498; Lung NCI460; Colon KM20L2 and Melanoma SK-MEL-3.

Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides

Dolastatin 10, a linear pentapeptide, has shown potent antineoplastic activity profiles against various experimental cancer systems. The design and synthesis of structural modifications of dolastatin 10 having significant antineoplastic activity against human cancer cell lines has been accomplished. Members of this group have demonstrated significant antineoplastic activity against selected human cancer cell lines. Especially: Ovarian OVSCAR-3; Central Nervous System ('CNS') SF295; Renal A498; Lung NCI460; Colon KM20L2 and Melanoma SK-MEL-3.

Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides

Growing community of inventors

Budapest, Hungary

Jozsef Barkoczy